The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NeoRAS: Incidence of RAS reversion from RAS mutated to RAS wild type.
 
Jason Henry
No Relationships to Disclose
 
Jason Willis
Honoraria - Cor2Ed; Cor2Ed; Cor2Ed; Cor2Ed
 
Christine Megerdichian Parseghian
No Relationships to Disclose
 
Kanwal Pratap Singh Raghav
Honoraria - Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; Eisai; Eisai
 
Benny Johnson
No Relationships to Disclose
 
Arvind Dasari
Consulting or Advisory Role - Abbvie/Stemcentrx; Abbvie/Stemcentrx; Abbvie/Stemcentrx; Abbvie/Stemcentrx; Ipsen; Ipsen; Ipsen; Ipsen; Lexicon; Lexicon; Lexicon; Lexicon; Novartis; Novartis; Novartis; Novartis; Voluntis; Voluntis; Voluntis; Voluntis
Research Funding - eFFECTOR Therapeutics; eFFECTOR Therapeutics; eFFECTOR Therapeutics; eFFECTOR Therapeutics; Eisai; Eisai; Eisai; Eisai; Guardant Health; Guardant Health; Guardant Health; Guardant Health; Hutchison MediPharma; Hutchison MediPharma; Hutchison MediPharma; Hutchison MediPharma; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis
 
David Stone
No Relationships to Disclose
 
Nikeshan Jeyakumar
No Relationships to Disclose
 
Oluwadara Coker
No Relationships to Disclose
 
Victoria M. Raymond
Employment - Guardant Health; Guardant Health; Guardant Health; Guardant Health; Trovagene; Trovagene; Trovagene; Trovagene
Stock and Other Ownership Interests - Guardant Health; Guardant Health; Guardant Health; Guardant Health; Trovagene; Trovagene; Trovagene; Trovagene
 
Richard B. Lanman
Employment - Guardant Health; Guardant Health; Guardant Health; Guardant Health; Veracyte; Veracyte; Veracyte; Veracyte
Leadership - Biolase; Biolase; Biolase; Biolase; Guardant Health; Guardant Health; Guardant Health; Guardant Health
Stock and Other Ownership Interests - Biolase; Biolase; Biolase; Biolase; Forward; Forward; Forward; Forward; Guardant Health; Guardant Health; Guardant Health; Guardant Health
Consulting or Advisory Role - Forward; Forward; Forward; Forward
Research Funding - Guardant Health; Guardant Health; Guardant Health; Guardant Health
 
Michael J. Overman
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Gritstone Bio; Gritstone Bio; Gritstone Bio; Gritstone Bio; MedImmune; MedImmune; MedImmune; MedImmune; Novartis; Novartis; Novartis; Novartis; Promega; Promega; Promega; Promega; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MedImmune; MedImmune; MedImmune; MedImmune; Merck; Merck; Merck; Merck; Roche; Roche; Roche; Roche
 
Scott Kopetz
Stock and Other Ownership Interests - MolecularMatch; MolecularMatch; MolecularMatch; MolecularMatch; Navire; Navire; Navire; Navire
Consulting or Advisory Role - Amal Therapeutics; Amal Therapeutics; Amal Therapeutics; Amal Therapeutics; Amgen; Amgen; Amgen; Amgen; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bayer Health; Bayer Health; Bayer Health; Bayer Health; Biocartis; Biocartis; Biocartis; Biocartis; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boston Biomedical; Boston Biomedical; Boston Biomedical; Boston Biomedical; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Genentech; Genentech; Genentech; Genentech; Holy Stone Healthcare; Holy Stone Healthcare; Holy Stone Healthcare; Holy Stone Healthcare; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Navire; Navire; Navire; Navire; Novartis; Novartis; Novartis; Novartis; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; Redx Pharma; Redx Pharma; Redx Pharma; Redx Pharma; Roche; Roche; Roche; Roche; Symphogen; Symphogen; Symphogen; Symphogen
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Biocartis (Inst); Biocartis (Inst); Biocartis (Inst); Biocartis (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Guardant Health (Inst); Guardant Health (Inst); Guardant Health (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst)